{"name":"Eiger BioPharmaceuticals","slug":"eiger-biopharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":15773000,"revenueGrowth":17,"grossMargin":0,"rdSpend":62331000,"netIncome":-74963000,"cash":38826000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo Lonafarnib","genericName":"Placebo Lonafarnib","slug":"placebo-lonafarnib","indication":"KRAS-mutant pancreatic cancer","status":"phase_3"}]}],"pipeline":[{"name":"Placebo Lonafarnib","genericName":"Placebo Lonafarnib","slug":"placebo-lonafarnib","phase":"phase_3","mechanism":"Lonafarnib inhibits farnesyltransferase, blocking the post-translational modification of proteins involved in cell proliferation and survival.","indications":["KRAS-mutant pancreatic cancer","HRAS-mutant head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUmNyY0lKYkVYMHZSZng1TExBT2dqX0VOUnhpOGNFNHlfalkxNlVCbnU2MENNSG1ScHZSczhhUHphaVlVSTNSWHhHaVRwUXNWZktKRFFKOEZBZG44aXR4SVVnSXo2Qnp0OFdNd1M1cW9JbFdFOFpQT2trWDlfRXo3ek9ZOTMya19UX1ZEQnM2QmNKSS00WnFQYjM0VzhwVTVxTmw1VjlZRWt2Zk9SX0hNM0lKeENmbzB1V0w3cFVERDN3dTQ?oc=5","date":"2026-01-31","type":"pipeline","source":"AD HOC NEWS","summary":"Eiger Biopharmaceuticals Shareholders Face Complete Loss as Liquidation Concludes - AD HOC NEWS","headline":"Eiger Biopharmaceuticals Shareholders Face Complete Loss as Liquidation Concludes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1fQWRZOW1UYmd5eEw5d2hubmFlR0pDZnNGRWFwSTVBcEdxWS1lTFU1VVZTdEtUMGZXM1RJT0lzYVU2eTBIa0F5cUNhaDRZYVoyOGhz?oc=5","date":"2025-01-21","type":"regulatory","source":"FirstWord Pharma","summary":"Amylyx's next ALS hopeful given clinical go-ahead by FDA - FirstWord Pharma","headline":"Amylyx's next ALS hopeful given clinical go-ahead by FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPcXlXcE5UT25Hd1FXZ24zOFYzMzBYYmVFRWJ0dDVqeHNvdVUtRzBPMm5tOGU0TlhPLUFyWlJPZzBRSW4tYnBXSkVBNkZOM2ljWC1XanAtdjlDaG13ejN3Vlh3bVU2S0hLa29KRjk0elFZX2gyWHBQdERVU1RrU2ZuYWZjZU5fcElBaWx4dVNZWllCNElwT2lOTkczSy14bk1JWWVtNXc3MFJEcTdKajdN?oc=5","date":"2024-10-01","type":"pipeline","source":"Investing.com","summary":"Eiger Biopharmaceuticals concludes chapter 11 process - Investing.com","headline":"Eiger Biopharmaceuticals concludes chapter 11 process","sentiment":"neutral"},{"date":"2024-10-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-09-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-09-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-09-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-08-26","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2024-08-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-08-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-07-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQX2FRME5VUTJnRFQ3alhRaUxjNElnTHhwTFR1QzdES0tUdm9PY0d3bUZBWmVkUWlaSlJPS1dlRTFQMXdzM2dyUElKbDVKTjhsdDJsVlpWaUFDbWNyRFhvbll2VWFXaTVJU2FnTlgyS1NmeHpWc3VtTWJmTnhObFJZSC1qdTEzeW5uU1Vzek9TUTAyVFZ6N0U5SHMtQU1vbnRBVG5JR3E1X29OV2dJYlg2dWhXbkVVUlhvRGI1eVhhbkJOOTBHX0xESkR2U195ekMwaUo1QWkzZ3FmMGFnVjM3QThYakt1aTJXc1VKRy1FU2daVDZROG5GMy1n?oc=5","date":"2024-07-12","type":"trial","source":"pharmexec.com","summary":"Amylyx Pharmaceuticals Acquires Phase III-Ready GLP-1 Receptor Agonist Avexitide for Hyperinsulinemic Hypoglycemia from Eiger BioPharmaceuticals - pharmexec.com","headline":"Amylyx Pharmaceuticals Acquires Phase III-Ready GLP-1 Receptor Agonist Avexitide for Hyperinsulinemic Hypoglycemia from ","sentiment":"neutral"},{"date":"2024-07-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-07-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPMHRFM3dVNTRkdHpoV09HVjZFYWhhSFNsWWFEelVjTjZSQnZXaE5wZXpKeUJaUmJBakhRRUNYb3NTNVd3SzdEZTFUMWN2MU81cHpKMUYtcHBlaHk5Z19wbWNobWpyZFhGOXJnQW5HTkhGbkU4ZHAweXpuVmlmejd3X2ttXzMwUnlIblNjXy02Wm43UVllZG9MUjY5RF8wVWVLRkFiSXRCNmpMNnpCcmVVbEJZRWZDRERkZ2RTUm5DLVNXdFo5dDRjOUJvTWdnS05HLUttbA?oc=5","date":"2024-06-21","type":"deal","source":"Reuters","summary":"Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar - Reuters","headline":"Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":15773000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":15773000,"period":"2023-12-31"},{"value":13484000,"period":"2022-12-31"},{"value":13484000,"period":"2022-12-31"},{"value":12142000,"period":"2021-12-31"},{"value":12142000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":62331000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-74963000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":38826000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}